Summary of Establishment Labs FY Conference Call Company Overview - **Company**: Establishment Labs (NasdaqCM: ESTA) - **Industry**: Medical Devices, specifically breast implants Key Points 2025 Performance and 2026 Outlook - Establishment Labs had an outstanding performance in 2025, exceeding initial expectations with the successful launch of the Motiva implant, opening 1,500 accounts, which was beyond the original plan [9][10] - The company expects strong momentum to continue into 2026, with guidance indicating at least 30% revenue growth, aiming for a midpoint revenue of $265 million [30][31] Drivers of Success - The success in 2025 was attributed to innovative marketing strategies, including partnerships with influencers and celebrities like Meghan Trainor, which significantly increased demand [13][15] - The company has been adding new accounts consistently, with a commercial team that reportedly hasn't gone a day without adding a new account [8][10] - The Preservé launch outside the U.S. has also been successful and is expected to drive growth in 2026 [11] Pricing Strategy - The pricing strategy for Motiva has been effective, with no significant pushback from the market. The company has maintained premium pricing due to the perceived value of their products [17][18] - Surgeons are reportedly charging a premium for procedures using Motiva, with increases of 30%-50% for those surgeries [46][50] Market Dynamics - The U.S. market has shown a stable demand for Ergonomix implants, with approximately 55%-60% of sales coming from this premium product line [21] - The company anticipates that the introduction of smaller size Motiva implants will capture an additional 10% of the market [65] International Business - Establishment Labs is focusing on direct markets, which offer better economics, and has seen healthy growth in international markets [71][72] - The company is optimistic about the Chinese market, expecting to achieve a dominant share similar to other Asian markets [73] Future Innovations and Expansion - The company is preparing for the reconstruction market, which could double their total addressable market (TAM). They are awaiting FDA approval for their reconstruction products [58][60] - Establishment Labs aims to democratize breast reconstruction and improve aesthetic outcomes, which could drive further adoption [63] Margin Expansion - The company expects gross margin expansion as they shift focus to higher-margin products and reduce dependency on distribution markets [67] Strategic Leadership Changes - The transition of CFO Raj Denhoy to a strategic role within the company is seen as a move to enhance business development and innovation initiatives [32][38] Additional Insights - The company has a conservative guidance approach, learning from market dynamics as they grow in the U.S. [31] - There is potential upside in revenue projections, particularly with the Preservé product line and the minimally invasive portfolio [74][76] This summary encapsulates the key insights from the Establishment Labs FY Conference Call, highlighting the company's strong performance, strategic initiatives, and future growth potential in the breast implant market.

Financial Data and Key Metrics Changes - Q4 2025 revenue was $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 reaching $211.1 million, up 27.2% from 2024 [3][4] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA was positive at $5.5 million, compared to a loss of $13.1 million in Q4 2024 [4][24] - The ending cash balance for 2025 was $75.6 million, indicating no need for additional capital [4] Business Line Data and Key Metrics Changes - U.S. Motiva revenue in 2025 was $45.6 million, contributing significantly to overall growth [3] - Gross margin for Q4 was 70.5%, a 200 basis point increase from the previous year, with overall gross profit margin increasing 330 basis points in 2025 [22][23] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global total sales in Q4, with strong growth in direct markets [22] - Latin America represented 18% of sales, with stable results in Brazil and strong growth in Argentina [22][23] - Asia Pacific accounted for 14.1% of sales, with improved performance in China [22][19] Company Strategy and Development Direction - The company aims to transform the breast aesthetics industry through innovation, with a focus on minimally invasive procedures like Preservé [6][12] - Plans to expand the U.S. sales force by adding up to 15 more representatives to drive market penetration [11][26] - The introduction of Motiva implants for breast reconstruction is expected to double the total addressable market in the U.S. [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026 and expects significant growth in 2027 [4][30] - The U.S. market remains healthy, with strong demand for breast augmentation procedures and a positive outlook for the minimally invasive portfolio [52][60] - The company is focused on maintaining operational momentum while preparing for future growth phases [20][21] Other Important Information - The company is actively working on FDA approvals for new products, including smaller sizes and reconstruction options, which are expected to enhance market share [18][69] - Establishment Labs is also considering refinancing options for its credit facility as it approaches the end of its term [26] Q&A Session Summary Question: Thoughts on the minimally invasive portfolio and market growth - Management noted strong early experiences with Preservé and Mia, indicating a positive trajectory for market growth and patient interest [33][35] Question: U.S. revenue and sales representative expansion - The company is focused on hiring experienced sales representatives to enhance market penetration and drive growth [36][38] Question: Plans for reconstruction market entry - Management highlighted the significant opportunity in the reconstruction market, with plans to expand the sales force and leverage existing relationships [40][41] Question: International growth and underlying demand - Management confirmed that international markets are showing healthy demand, with no significant one-off factors affecting growth [43][44] Question: Global market conditions and augmentation procedures - The overall market for breast augmentation procedures is healthy, with increasing interest and demand across various regions [51][54] Question: Contribution of pipeline products to revenue guidance - Reconstruction is expected to be more of a 2027 story, while Preservé is anticipated to drive significant revenue growth in 2026 [68][70]

Financial Data and Key Metrics Changes - Q4 2025 revenue reached $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 at $211.1 million, up 27.2% from 2024 [4][22] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA for Q4 was $5.5 million, a significant improvement from a loss of $13.1 million in Q4 2024 [5][24] - The company ended 2025 with a cash balance of $75.6 million, indicating no need for additional capital [5] Business Line Data and Key Metrics Changes - U.S. Motiva revenue for 2025 was $45.6 million, significantly exceeding expectations, contributing to approximately 20% market share by the end of 2025 [6][22] - Gross margin for Q4 was 70%, marking the second consecutive quarter of achieving this level, with an overall increase of 330 basis points in gross profit margin for 2025 compared to 2024 [4][23] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global sales in Q4, with strong growth in direct markets exceeding 20% [22] - Latin America represented 18% of sales, with Brazil stabilizing and Argentina showing strong growth [22] - Asia Pacific contributed 14.1% to sales, with improved performance in China noted [22][19] Company Strategy and Development Direction - The company aims to transform the breast aesthetics industry through innovation, with a strong R&D pipeline since 2010 [6][8] - Plans to expand the U.S. sales force by adding up to 15 more representatives to drive market share [11] - The introduction of minimally invasive breast augmentation through Preservé is expected to significantly expand the market and procedure volumes [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026 and anticipates significant growth in 2027 [5][30] - The company highlighted a healthy demand across all markets, with expectations for continued strong performance in the U.S. and international markets [27][52] - Management noted that the adoption of Motiva is still early, with significant room for growth in practice adoption and account penetration [27][60] Other Important Information - The company is actively working on FDA approvals for new products, including Motiva implants for breast reconstruction, which could double the total addressable market in the U.S. [17][70] - The transition in management roles is aimed at sustaining operational momentum and ensuring oversight of strategic initiatives [20][21] Q&A Session Summary Question: Insights on the minimally invasive portfolio and market growth - Management noted positive early experiences with the minimally invasive platform, indicating it could drive significant market growth and bring new patients to breast augmentation [33][35] Question: U.S. revenue growth and sales representative strategy - The company is focused on hiring experienced sales representatives from the industry to enhance productivity and drive growth in the U.S. market [36][39] Question: Plans for reconstruction market entry and sales strategy - Management discussed the importance of expanding the sales force and establishing hospital contracts to capitalize on the reconstruction market opportunity [41][42] Question: International growth and underlying demand - Management confirmed that international growth is stable, with no significant one-off factors affecting results, driven by strong demand and execution [44][45] Question: Expectations for the Chinese market and growth hurdles - The company is optimistic about the Chinese market, noting improvements in distributor performance and a focus on building commercial capabilities [83][84]